Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploiting Circulating Tumour DNA to Intensify Postoperative Treatment of Colon Cancer (ERASE-CRC)
NCT05062889Phase 2Suspended
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- May 2023
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Nanoparticles, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, trifluridine + tipiracil, trastuzumab, tucatinib in colon cancer, sponsored by Gruppo Oncologico Nord Ovest. Started May 2023; status: suspended.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabtrifluridine + tipiraciltrastuzumabtucatinib
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05062889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062889.